-
Clin Cancer Res: A biomarker that predicts response to treatment with sintilimab combined with IBI305 in advanced hepatocellular carcinoma!
Time of Update: 2022-04-22
Sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab are antiangiogenic drugs in the standard systemic treatment of advanced hepatocellular carcinoma, but the median overall survival is only 10.
-
Nature sub-journal: Laser-accelerated proton beam irradiation for tumor therapy
Time of Update: 2022-04-22
The research team constructed a research platform that enables ultra-high peak dose rate irradiation of tumors in small animal models using a proton beam from a laser plasma accelerator .
-
Clin Cancer Res: Fudan Tumor's new therapy for advanced immunomodulatory triple-negative breast cancer (TNBC) with an effective rate of 95.8%
Time of Update: 2022-04-22
In conclusion, the study shows that the triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC .
-
J Clin Oncol: Appropriate adjuvant radiotherapy after radical prostatectomy for stage pN1 prostate cancer reduces long-term mortality!
Time of Update: 2022-04-22
For patients with pN1 prostate cancer, appropriate adjuvant radiotherapy after early radical prostatectomy can reduce the risk of subsequent all-cause mortality, and the reduction effect is more significant with the number of positive pelvic lymph nodes .
-
Cancers: Prognostic value of adjuvant chemotherapy in patients with mucinous colorectal adenocarcinoma without distant metastasis
Time of Update: 2022-04-22
Studies have shown that the prognosis of mucinous adenocarcinoma (MAC) patients is worse than that of adenocarcinoma (AC) patients, especially in stage III patients, and adjuvant chemotherapy does not significantly improve the prognosis of patients .
-
Eur J Cancer: Histological transformation probability and clinical course of EGFR-mutant lung cancer
Time of Update: 2022-04-22
Lung cancerNSCLCThis study is a multicenter, retrospective cohort study of patients with EGFR-mutant advanced lung cancer treated with EGFR tyrosine kinase inhibitor (TKI) between 2012 and 2019 to identify patients with histologically converted Incidence and clinical course of EGFR-mutated lung cancer .
-
PNAS: D-mannose promotes immunotherapy and radiotherapy in triple-negative breast cancer by degrading PD-L1
Time of Update: 2022-04-22
breast cancer immunityOn February 22, 2022, Lu Lei's team from Fudan University School of Basic Medicine, Xu Yanping's team from Tongji University and Zhang Song's team from Nankai University jointly published a paper on PNAS entitled D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of Research results of PD-L1 .
-
Eur J Cancer: Effects of diabetes and metformin on recurrence risk and prognosis in colon cancer patients
Time of Update: 2022-04-22
In conclusion, colon cancer patients with diabetes had a shorter time to recurrence and a worse survival prognosis than colon cancer patients without diabetes .
Colon cancer patients with diabetes had a shorter time to recurrence and a worse survival prognosis compared with colon cancer patients without diabetes.
-
Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer
Time of Update: 2022-04-22
Recently, a team from the Fifth Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the safety and efficacy of nivolumab (nivolumab) combined with recombinant human endostatin in previously treated advanced non-small cell lung cancer (NSCLC) .
-
Lancet Oncol: Lucaparib as an Alternative to Chemotherapy for BRCA1/2 Mutant Recurrent Ovarian Cancer
Time of Update: 2022-04-22
The aim of this study was to evaluate the efficacy of the PARP inhibitor lucaparib versus platinum-based and non-platinum-based chemotherapy in BRCA1/2-mutated ovarian cancer .
In the efficacy analysis population (220 in the rucaparib group and 105 in the chemotherapy group), the median progression-free survival was 7.
-
Mol Cancer: Novel biomarker SNORD33 predicts sensitivity to platinum-based chemotherapy in triple-negative breast cancer
Time of Update: 2022-04-22
Researcher Chen Yu from School of Basic Medicine, Fudan University, Professor Wang Biyun from Affiliated Cancer Hospital, and Professor Fu Chaowei from School of Public Health collaborated to discover the predictive effect of plasma small nucleolar RNA SNORD33 on platinum sensitivity in triple-negative breast cancer patients, and revealed methyl The protein binding protein MeCP2 is involved in the molecular mechanism of platinum resistance regulated by SNORD33 .
-
[Nature sub-issue] Designing a "stealth coat" for bacteria to deliver drugs to tumors and kill cancer cells!
Time of Update: 2022-04-22
Bacterial cancer therapy has unique advantages over conventional drug therapy!Columbia University School of Engineering researchers report they have developed a "stealth" system that temporarily hides therapeutic bacteria from the immune system, allowing them to more efficiently deliver drugs to tumors that kill mice of cancer cells .
-
European Radiology: The value of DW MRI in predicting early response to neoadjuvant chemotherapy in breast cancer
Time of Update: 2022-04-22
Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements .
1007/s00330- 021-08462-zNathalie A Hottat Dominique A Badr Sophie Lecomte ,et al Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements 10.
-
Int J Cancer: Does the number of pigmented moles correlate with cancer risk?
Time of Update: 2022-04-22
Any cancer excludes skin cancer; blood diseases includes leukemia and lymphoma; head and neck excludes lip cancer; basal cell carcinoma; squamous cell carcinoma, squamous cell carcinoma of the skinFigure 2 Association of genetically predicted mole counts with individual or overall cancer risk according to mole count quartile polygenic risk score (PRS) using individual-level data from the QSkin cohort .
-
JITC: Huazhong University of Science and Technology team found a new way to enhance immunotherapy!
Time of Update: 2022-04-22
A recent study by Xu Shuangbing and Wu Gang's team from the Tumor Center of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology showed that in the treatment of lung cancer, inhibition of lysine-specific demethylase 4C ( KDM4C ) can promote CXCL10 gene transcription, Enhances antitumor immunity mediated by CD8+ T cells .
-
Oncologist: Real-world assessment of the impact of age at diagnosis on the treatment and prognosis of metastatic pancreatic ductal adenocarcinoma
Time of Update: 2022-04-22
Therefore, a team from the United States conducted a real-world study to assess the characteristics, treatment rates, and survival outcomes of patients with metastatic PDAC (mPDAC) based on age at diagnosis .
-
Clin Cancer Res: bimetinib combined with ribocillin for NRAS-mutated melanoma
Time of Update: 2022-04-22
In conclusion, the combination regimen of bimetinib and ribocillin can be safely used in NRAS-mutated melanoma patients with positive therapeutic activity .
The combination regimen of bimetinib and ribocillin can be safely used in patients with NRAS-mutated melanoma and has positive therapeutic activity .
-
Lancet Oncol: Efficacy of pembrolizumab in classic or endemic Kaposi's sarcoma
Time of Update: 2022-04-22
The aim of this study was to evaluate the therapeutic activity of pembrolizumab in classical and endemic Kaposi's sarcoma requiring systemic therapy .
PD-1 blockade with prebrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
-
Clin Cancer Res: Nivolumab significantly prolongs long-term survival in advanced esophageal squamous cell carcinoma
Time of Update: 2022-04-22
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3 )
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3 )
-
JAMA sub-issue: More than 90% of cancer patients develop antibodies after COVID-19 vaccination!
Time of Update: 2022-04-22
Taken together, the results of this cohort study suggest that patients with solid tumors or hematological tumors develop an immune response following the COVID-19 vaccine, albeit at lower levels of antibodies than adults without cancer .